About IJCPCR

OLFACTORY IMPAIRMENT IN PARKINSON'S DISEASE PROGRESSION: QUANTITATIVE ASSESSMENT OF ODOR RECOGNITION THRESHOLDS AND IDENTIFICATION OF POTENTIAL BIOMARKER ODORANTS
Article Information
Language
Corres.Author
Email
Accepted Date
File size
No of Downloads
Published by
Full Text
Patients with Parkinson's disease (PD) commonly exhibit these symptoms olfactory involvement. With the help of different types and concentrations of odorants, we conducted a quantitative study to examine the function of smell in people with Parkinson's disease. In this study, we sought to determine whether a particular odour can influence PD patients' severity and duration. Study participants included 89 patients with nondemented PD and 20 other patients with similar age profiles. Tests using T and T olfactometers were used to assess smell function quantitatively. Various concentrations of five types of odorants are used in this test. Hoehn and Yale (HY) patients with Parkinson's disease in five groups stages I (n = 24), II (n = 48), III (n = 86), and IV (n = 20) and 40 controls (n = 40) performed odor recognition thresholds (RT) for all five odorants and for each individual odor. In order to compare the five groups, one-way analysis of variance was used as well as Ryan's method. A significant difference was found Comparison of the total RT scores of HY II, III, and IV patients with those of controls and HY I patients. HT I and control were no statistically significant differences between the groups in RT scores. In contrast, three patients from HY I (25%) had total RT scores over two standard deviations above the mean of the controls. The RT scores for methylcyclopentenolone and skatol are significantly higher when compared with HY II, III, and IV patients and controls. In comparison with control subjects, PD patients did not exhibit any statistically significant differences in these three odorants. Based on the present study, hyposmia became more common in PD patients as they progressed through HY II. Olfactory Parkinson's disease patients' evaluation was improved with methyl cyclopentenolone or skatol as a single odorant. It was also confirmed that some patients with HY I had olfactory deficits. It is important to continue to study prospectively HY I patients with hyposmia to determine if they have a different profile of PDddd